Ameriprise Financial Inc. purchased a new position in Viemed Healthcare, Inc. (NASDAQ:VMD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 42,418 shares of the company's stock, valued at approximately $340,000. Ameriprise Financial Inc. owned about 0.11% of Viemed Healthcare at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Rice Hall James & Associates LLC acquired a new position in shares of Viemed Healthcare during the 4th quarter valued at $2,083,000. First Eagle Investment Management LLC raised its stake in shares of Viemed Healthcare by 196.5% in the 4th quarter. First Eagle Investment Management LLC now owns 328,824 shares of the company's stock worth $2,637,000 after buying an additional 217,923 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Viemed Healthcare in the 4th quarter worth $1,549,000. JPMorgan Chase & Co. raised its stake in shares of Viemed Healthcare by 131.4% in the 4th quarter. JPMorgan Chase & Co. now owns 228,652 shares of the company's stock worth $1,834,000 after buying an additional 129,854 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Viemed Healthcare in the 4th quarter worth $468,000. Institutional investors own 74.24% of the company's stock.
Viemed Healthcare Price Performance
Shares of NASDAQ VMD traded up $0.15 during mid-day trading on Monday, reaching $6.87. The company had a trading volume of 329,257 shares, compared to its average volume of 141,009. The company has a current ratio of 1.31, a quick ratio of 1.19 and a debt-to-equity ratio of 0.03. The stock has a market cap of $271.53 million, a PE ratio of 25.44 and a beta of 1.38. The company has a 50-day moving average price of $6.76 and a two-hundred day moving average price of $7.58. Viemed Healthcare, Inc. has a 1-year low of $6.14 and a 1-year high of $9.81.
Viemed Healthcare (NASDAQ:VMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. The business had revenue of $59.10 million for the quarter, compared to analysts' expectations of $60.60 million. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%.
Viemed Healthcare Profile
(
Free Report)
Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Further Reading
Before you consider Viemed Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viemed Healthcare wasn't on the list.
While Viemed Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
